GMED Stock Overview
A medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Globus Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$82.63 |
| 52 Week High | US$87.22 |
| 52 Week Low | US$49.33 |
| Beta | 1.19 |
| 1 Month Change | -2.47% |
| 3 Month Change | 16.02% |
| 1 Year Change | 53.96% |
| 3 Year Change | 14.41% |
| 5 Year Change | 40.34% |
| Change since IPO | 512.07% |
Recent News & Updates
Recent updates
Globus Medical Stock: Re-Rated After A Solid Year
Nov 18Globus Medical (NYSE:GMED) Has A Rock Solid Balance Sheet
Nov 04
Globus Medical, Inc.'s (NYSE:GMED) Shareholders Might Be Looking For Exit
Oct 14Globus Medical: A Post Acquisition Analysis
Aug 26Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors
Jun 28An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued
Apr 08Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly
Mar 20Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock
Feb 27Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?
Feb 09Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings
Jan 17Globus Medical: Merger Overhang Lingering
Nov 27Globus Medical: Almost Having My Back
Sep 13Globus Medical: Slightly Too Pricey Right Now
Aug 07Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy
Jul 18Globus Medical Q4 2022 Earnings Preview
Feb 20Globus Medical: An Impressive Long-Term Revenue Growth Play
Jan 08Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line
Nov 08Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact
Sep 02Shareholder Returns
| GMED | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.3% | -1.5% | -2.4% |
| 1Y | 54.0% | 10.0% | 23.4% |
Return vs Industry: GMED exceeded the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: GMED exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| GMED volatility | |
|---|---|
| GMED Average Weekly Movement | 3.7% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GMED has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GMED's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 5,000 | Dan Scavilla | www.globusmedical.com |
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants.
Globus Medical, Inc. Fundamentals Summary
| GMED fundamental statistics | |
|---|---|
| Market cap | US$11.25b |
| Earnings (TTM) | US$91.51m |
| Revenue (TTM) | US$2.48b |
122.9x
P/E Ratio4.5x
P/S RatioIs GMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GMED income statement (TTM) | |
|---|---|
| Revenue | US$2.48b |
| Cost of Revenue | US$816.66m |
| Gross Profit | US$1.66b |
| Other Expenses | US$1.57b |
| Earnings | US$91.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.67 |
| Gross Margin | 67.05% |
| Net Profit Margin | 3.69% |
| Debt/Equity Ratio | 10.7% |
How did GMED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:08 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Globus Medical, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Wittes | Aegis Capital Corporation |
| Ishan Majumdar | Baptista Research |
| Matt Miksic | Barclays |